NVS-PAK1-1_COA_25045_MedChemExpress
3_种常用碳青霉烯类抗生素血药浓度UPLC-MS
3种常用碳青霉烯类抗生素血药浓度UPLC-MS/MS检测方法的建立Δ秦怡1＊，张瑞霞2，吕雅瑶2，翁莉莉1，张弋2 #（1.天津医科大学一中心临床学院，天津 300192；2.天津市第一中心医院药学部，天津 300192）中图分类号 R917；R978.1文献标志码 A 文章编号 1001-0408（2024）03-0343-05DOI 10.6039/j.issn.1001-0408.2024.03.14摘要目的建立3种临床常用碳青霉烯类抗生素——厄他培南（ETP）、亚胺培南（IPM）、美罗培南（MEM）血药浓度检测的超高效液相色谱-质谱联用（UPLC-MS/MS）法。
方法血浆样品经甲醇沉淀蛋白后，以3种抗生素的稳定性同位素（ETP-D4、IPM-D4、MEM-D6）为内标，采用ACQUITY UPLC BEH C18（2.1 mm×50 mm，1.7μm）色谱柱分离；流动相为98%乙腈+2%水+0.1%甲酸和98%水+2%乙腈+0.1%甲酸，梯度洗脱；流速为0.3 mL/min；柱温为40 ℃；采用正离子、多反应监测模式进行扫描分析。
结果该方法专属性良好，在ETP、IPM、MEM 0.2～200、0.1～100、0.1～100μg/mL范围内线性良好（r2≥0.993），批内、批间精密度和准确度良好（RE均≤5.14%，RSD均≤11.15%），基质效应、提取回收率较一致（RSD≤12.99%）。
结论本实验建立了一种可以同时定量ETP、IPM、MEM血药浓度的UPLC-MS/MS法，该方法样品前处理简单、检测时间短、所需样品量少，可满足临床需求。
关键词碳青霉烯类抗生素；超高效液相色谱-质谱联用；血药浓度；厄他培南；亚胺培南；美罗培南Establishment of UPLC-MS/MS method for the determination of plasma concentration of three common carbapenem antibioticsQIN Yi1，ZHANG Ruixia2，LYU Yayao2，WENG Lili1，ZHANG Yi2（1. First Central Clinical College of Tianjin Medical University，Tianjin 300192，China；2. Dept. of Pharmacy，Tianjin First Central Clinical Hospital，Tianjin 300192， China）ABSTRACT OBJECTIVE To establish a UPLC-MS/MS method for the determination of plasma concentration of three carbapenem antibiotics，i.e. ertapenem （ETP），imipenem （IPM）and meropenem （MEM）.METHODS After protein precipitation with methanol，the plasma samples were separated by ACQUITY UPLC BEH C18column （2.1mm×50mm，1.7μm）using stable isotopes of three antibiotics （ETP-D4，IPM-D4，MEM-D6）as the internal standard. The mobile phases were 98%acetonitrile +2% water +0.1%formic acid and 98%water +2%acetonitrile +0.1%formic acid，by gradient elution. The flow rate was 0.3mL/min and the column temperature was 40 ℃. Scanning analysis was performed in the positive ion and multiple reaction monitoring mode. RESULTS The method had good specificity，good linearity （r2≥0.993）in the range of 0.2-200，0.1-100and 0.1-100μg/mL of ETP，IPM and MEM，and good intra-batch and inter-batch precision and accuracy （all RE≤5.14%，all RSD≤11.15%），the matrix effect and extraction recovery were consistent （RSD≤12.99%）. CONCLUSIONS This study establishes the UPLC-MS/MS method to simultaneously quantify the plasma concentration of ETP，IPM and MEM. The method has the advantages of simple pretreatment， short detection time and small sample quantity to meet clinical requirement.KEYWORDS carbapenem antibiotics； UPLC-MS/MS； plasma concentration； ertapenem； imipenem； meropenem碳青霉烯类抗生素具有抗菌谱广、抗菌活性强、耐药率低的特点，已成为治疗重症感染的主要选择。
219526299_丁二磺酸腺苷蛋氨酸联合多烯磷脂酰胆碱治疗妊娠期肝内胆汁淤积症的效果及对母婴结局的
丁二磺酸腺苷蛋氨酸联合多烯磷脂酰胆碱治疗妊娠期肝内胆汁淤积症的效果及对母婴结局的影响陈徐① 周艳① 石敏① 【摘要】 目的：针对妊娠期肝内胆汁淤积症（ICP）患者实施丁二磺酸腺苷蛋氨酸联合多烯磷脂酰胆碱治疗，分析其效果及对母婴结局的影响。
方法：选取2018年1月─2021年12月崇州市人民医院收治的126例ICP患者为研究对象。
按照治疗方法的不同将其分为观察组（n=84）和对照组（n=42）。
两组均实施常规治疗，在此基础上，对照组给予丁二磺酸腺苷蛋氨酸治疗，观察组给予丁二磺酸腺苷蛋氨酸联合多烯磷脂酰胆碱治疗。
比较两组皮肤瘙痒程度评分、生化指标水平及母婴结局。
结果：治疗第7天、14天，两组皮肤瘙痒程度评分均较治疗前降低，且观察组明显低于对照组，差异有统计学意义（P<0.05）。
治疗第14天，两组天门冬酸氨基转移酶（AST）、丙氨酸氨基转移酶（ALT）、总胆红素（TBIL）、总胆汁酸（TBA）均较治疗前改善，且观察组AST、ALT、TBIL、TBA低于对照组，差异有统计学意义（P<0.05）。
观察组剖宫产、胎盘前置、羊水异常、产后出血及妊娠期高血压疾病发生率均低于对照组，差异有统计学意义（P<0.05）；两组均未发生死亡事件，观察组胎儿宫内窘迫、早产及新生儿窒息发生率明显低于对照组，差异有统计学意义（P<0.05）。
结论：采用丁二磺酸腺苷蛋氨酸联合多烯磷脂酰胆碱的治疗方案，能够有效缓解ICP患者的皮肤瘙痒程度，使其生化指标得以显著改善，有效保障母婴安全。
【关键词】 丁二磺酸腺苷蛋氨酸 多烯磷脂酰胆碱 妊娠期肝内胆汁淤积症 母婴结局 doi：10.14033/ki.cfmr.2023.17.012 文献标识码 B 文章编号 1674-6805（2023）17-0047-04 Effect of Adenosine Methionine Succinate Combined with Polyene Phosphatidylcholine on Intrahepatic Cholestasis of Pregnancy and Its Influence on Maternal and Infant Outcomes/CHEN Xu, ZHOU Yan, SHI Min. //Chinese and Foreign Medical Research, 2023, 21(17): 47-50 [Abstract] Objective: To analyze the effect of Adenosine Methionine Succinate combined with Polyene Phosphatidylcholine in the treatment of intrahepatic cholestasis of pregnancy (ICP) patients and its impact on maternal and infant outcomes. Method: A total of 126 ICP patients admitted to Chongzhou People's Hospital from January 2018 to December 2021 were selected as the study subjects. According to different treatment methods, they were divided into observation group (n=84) and control group (n=42). Both groups received conventional treatment, on this basis, the control group was given Adenosine Methionine Succinate and the observation group was given Adenosine Methionine Succinate combined with Polyene Phosphatidylcholine. The skin pruritus score, biochemical index level and maternal and infant outcomes were compared between the two groups. Result: On the 7th and 14th day of treatment, the score of itching degree of skin in both groups were lower than before treatment, and the observation group were significantly lower than the control group, the differences were statistically significant (P<0.05). On the 14th day of treatment, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (TBIL) and total bile acid (TBA) in both groups were improved compared with before treatment, and the AST, ALT, TBIL and TBA in the observation group were lower than those in the control group, the differences were statistically significant (P<0.05). The incidence of cesarean section, placenta previa, abnormal amniotic fluid, postpartum hemorrhage, and gestational hypertension in the observation group were lower than those in the control group, the differences were statistically significant (P<0.05); there were no deaths in either group, and the incidence of fetal distress, premature birth, and neonatal asphyxia in the observation group were significantly lower than those in the control group, the differences were statistically significant (P<0.05). Conclusion: The combination of Adenosine Methionine Succinate combined with Polyene Phosphatidylcholine can effectively relieve the degree of itching of the skin in ICP patients, improve the biochemical indexes significantly, and effectively protect the safety of mothers and children. [Key words] Adenosine Methionine Succinate Polyene Phosphatidylcholine Intrahepatic cholestasis of pregnancy Maternal and infant outcomes First-author's address: Chongzhou People's Hospital, Chongzhou 611230, China①崇州市人民医院 四川 崇州 611230 妊娠期肝内胆汁淤积症（ICP）发生于女性妊娠期，是一种发生率相对较低的妊娠期疾病，往往好发于妊娠中晚期，主要表现为皮肤瘙痒，给患者带来较大的痛苦，严重影响其日常工作与生活[1]。
体外诊断生化试剂应用参数
CHEMISTRY ACP ALB ALP ALT AM 货号270010036008201110060180006051000503601850111018018001803601870111050018005003600930TEST ACP ALB ALP ALT AM SAMPLE VOL．20371025 DILUTION0101000 REAGENT VOL.1-STEP250300270290250 DILUTION00000 2-STEP50[N] DILUTION00000 WAVE-LENGTH-1410600410340340 WAVE-LENGTH-2450700480410700 METHOD RATE END RATE RATE END REACTION+++--FIRST-POINT-160439 LAST-POINT-1166161616 FIRST-POINT-2N/A N/A N/A N/A N/A LAST-POINT-2N/A N/A N/A N/A N/A NO LAG-TIME YES NO YES YES NO TURBIDITY NO NO NO NO NO PROZONE CHECK NO NO NO NO NO REAGENT OD L-0.5-0.5-0.5-0.5-0.5 H 2.5 2.5 2.5 2.5 2.5 SERUM BLANK L N/A N/A N/A N/A N/A REAGENT OD H N/A N/A N/A N/A N/A MIN-OD-0.5-0.5-0.5-0.5-0.5 MAX-OD 2.0 2.0 2.0 2.0 2.0 LINEARITYDYNAMIC RANGE L00000 H8060100010001180 UNIT U/L g/L U/L U/L umol/L CORRELATION FACTORA=11111 B=00000 COUNT11111 DILUTION VOLUME00000 CONDENSE VOLUME00000 MONITOR SPAN11111 AGC POINT00000 K.FACTOR1308.42628.260780上述参数仅供参考，详情请参阅试剂说明及仪器说明。
大动脉炎患者外周血单个核细胞RT-qPCR内参基因的选择
January 2021Vol.41 No.12021 年 1 月 第 41 卷 第 1 期基础医学与临床Basic & Clinical Medicine文章编号：1001-6325 ( 2021 ) 01-0087-06研究论文大动脉炎患者外周血单个核细胞RT-qPCR 内参基因的选择田苡箫，李菁*收稿日期：2019-11-18 修回日期：2020-04-30*通信作者(corresponding author ) ：lijing6515@ （中国医学科学院北京协和医学院北京协和医院风湿免疫科风湿免疫病学教育部重点实验室国家皮肤与免疫疾病临床医学研究中心，北京100032）扌摘要：目的筛选适于在大动脉炎（TAK ）患者和健康人群（HC ）之间比较外周血单个核细胞（PBMC ）中mRNA 表达水平的内参基因。
方法提取PBMC 中的总RNA,应用RT-qPCR ，分别采用geNorm 、NormFinder 、BestKeeper 3种软 件程序，分析 3-glucuronidase ,GAPDH ,ACTB ,SDHA ,HPRT1,RPL13A ,B2M , YWHAZ 和 PKG1 9 个基因的 mRNA 表达稳定性。
以T-bet 、GATA3和RORC 作为目的基因，比较不同稳定性的内参基因对mRNA 相对丰度的影响。
结果geNorm 筛选得到的基因组合为B 2M-SDHA , Nor^nFinder 和BestKeeper 筛选出最稳定的内参基因均为HPRT1 ； 3种方法均显示GAPDH 的稳定性较差。
结论自身免疫病患者在接受免疫抑制药物治疗时,原本稳定表达的基因可能会 上调或下调;在样本量较小时，稳定性更好的内参基因可能更有助于检测组间差异。
关键词：大动脉炎;实时定量聚合酶链式反应;RNA 稳定性；内参基因选择中图分类号:R593.2 文献标志码:AValidation of reference genes for the normalization of the RT-qPCRin peripheral blood mononuclear cells of patients with Takayasu arteritisTIAN Yi-xiao ， LI Jing *(Department of Rheumatology and Immunology , Key Laboratory of Rheumatology and Clinical Immunology , Ministry of Education ,National Clinical Research Center for Dermatologic and Immunologic Diseases ( NCRC-DID ),Peking Union Medical College Hospital , CAMS & PUMC , Beijing 100032, China)Abstract ： Objective To validate proper reference genes for quantitative real-time polymerase chain reaction ( RT-qPCR) used for comparing mRNA expression levels in Takayasu arteritis" (TAK) and healthy controls' ( HC ) pe ripheral blood mononuclear cells ( PBMC ). Methods Total RNA in PBMCs was extracted and used RT-qPCR to determine the profiles of 9 candidate genes , including 0-glucuronidase, GAPDH , ACTB , SDHA , HPRT1, RPL13A , B2M , YWHAZ and PKG1. Then compared their transcription stability by geNorm , NormFinder , and Best Keeper. Afterwards , with T-bet , GATA3 and RORC as the targeted genes , explored the influence of reference genes with different stability on mRNA relative abundance. Results The gene combination of B2M-SDHA was selected bygeNorm , and HPRT1 was the most stable one in analysis results of NormFinder and BestKeeper , while GAPDH was less stable. Conclusions Genes that have been expressed stably may be upregulated or downregulated whenpatients with autoimmune diseases received immunosuppressive drugs. When the sample size is small ， the more sta ble internal reference may facilitate the identification of inter-groups difference.Key words : Takayasu arteritis ； real-time polymerase chain reaction ； RNA stability ； selection of reference gene88基础医学与临床Basic&Clinical Medicine2021.41(1)反转录实时荧光定量聚合酶链式反应（reverse quantitative real-time polymerase chain reaction,RT-qPCR）是目前分析基因表达水平的黄金标准，却经常表现出重复性欠佳的问题，选取合适的内参基因有助于改善这一情况［1］。
26291346_基于UPLC-MS
Abstract: A UPLC-MS/MS method was established to quantitatively determine the content of alliin in animal plasma to study whether alliin and alliin in garlic enteric preparations can react to produce the active ingredient allicin in the in vivo environment. Methods Reversed-phase C18 column (Waters ICQUITY UPLC BEH, 100 × 2.1 mm, 1.7μm), column temperature: 40 ℃, flow rate: 0.15 mL/min, injection volume: 2μl, Mobile phase: 0.1% formic acid (A)-acetonitrile (B), gradient elution; mass spectrometry ionization: ESI+, determination of allicin in rat plasma . Results The results of two parallel experiments of garlic enteric preparation and enzymatic garlic powder showed that in the garlic enteric preparation with allinase, the plasma concentration of alliin in the blood of rats was significantly lower. Conclusion A UPLC-MS/MS method for the quantitative determination of alliin in animal plasma has been established. Alliin and alliin in garlic enteric-coated preparations can react in vivo.Key words: Garlic enteric preparation; garbonine; UPLC-MS-MS基于UPLC-MS/MS大蒜肠溶制剂中蒜氨酸、蒜酶体内反应情况研究杨亮1，胡小霞4 ，宋百灵4，关明3，李新霞2*（1.新疆警察学院 新疆 乌鲁木齐 8300112.新疆医科大学药学院 新疆 乌鲁木齐 8300113.新疆师范大学化学化工学院 新疆 乌鲁木齐 8300544.新疆医科大学中心实验室 新疆 乌鲁木齐 830011）Study on the Reaction of Garlic and Uterine in the UPLC-MS / MS of Garlic SausolYANG Liang 1，HU Xiaoxia 4 ，SONG Bailing 4，GUAN Ming 3，LI Xinxia 2*(1. Xinjiang Police College, Urumqi 830054, Xinjiang China2.Chemistry and Chemical Engineering of Xinjiang Normal University College, Urumqi 830054, Xinjiang China3.School of Pharmacy, Xinjiang Medical University, Urumqi 830011, Xinjiang China4.Central Laboratory of Xinjiang Medical University, Urumqi 830011, Xinjiang China ）摘要：目的 建立定量测定动物血浆中蒜氨酸含量的UPLC-MS/MS 方法，研究大蒜肠溶制剂中蒜氨酸、蒜酶能否在体内环境下反应生成活性成分大蒜辣素。
美国贝克曼库尔特流式细胞分析仪
美国贝克曼库尔特流式细胞分析仪（Beckman coulter cell）产品型号：Cell Lab Quanta SC当前价格：0.00元产品数量：0新旧程度：全新有效期至：0000-00-00所在地：产品简介：仪器简介：T细胞亚群检测的CD45/CD4/CD8/CD3、CD45/CD56/CD19/CD3；阵发性血红蛋白尿（PNH）检测的CD55、CD59；血小板无力症（GT）检测的CD41、CD61等等详细信息仪器简介：T细胞亚群检测的CD45/CD4/CD8/CD3、CD45/CD56/CD19/CD3；阵发性血红蛋白尿（PNH）检测的CD55、CD59；血小板无力症（GT）检测的CD41、CD61等等。
但对于白血病/淋巴瘤免疫分型，国际上迄今为止也没有统一的抗体组合。
在2000年国际细胞分析学会（ISAC）大会上，临床血细胞计数协会组织了一次国际专家会议，以期对检测血液淋巴系统肿瘤所需最少、最有效的单抗数达成共识。
75%与会者一致认为，对于慢性淋巴系统增殖性疾病（CLD）有9种单抗：CD5,CD19,κ,λ,CD3,CD20,CD23,CD10,CD45对初诊来说是最基本的。
淋巴瘤和CLD相似，需要至少12-16种单抗。
对于急性白血病（AL），75%的与会者认为大约13-15种单抗是最基本的：CD10,CD19,CD79a,CD13,CD33,CD34,CD45,CD2,MPO，CD7,CD14,CD3,HLA-DR等，对初步鉴别白血病系列是必需的。
其他一些（CD16,CD56,CDw65,TdT,cyCD3）可能对某些病例有用。
几乎所有的投票者都认为，要对急性白血病完善分类所需单抗的恰当数量平均为20-24种。
但这些抗体之间组合也是一大难题，目前也无统一规定（如表二）。
大会多数发言者(11/13)指出，对已确诊病人的监护和分期来说，仅需较少单抗。
抗体的质量控制是实验的关键环节。
抗体的质量包括其特异性、灵敏度、精密度。
MEDICA EasyRA
REF 10213-4 4 x 24mL总蛋白 (TP)楔形瓶，每瓶含试剂可用量 24mL。
预期用途EasyRA® TP 试剂目的是用于通过 MEDICA EasyRA 临床化学分析仪进行人血清或血浆（采用肝素锂作为抗凝血剂）中总蛋白的定量测定。
仅用于体外诊断用途。
仅供专业人员使用。
摘要和说明1, 2, 3在人血清中，血清蛋白主要包括白蛋白（占总蛋白的50-60%），其余部分包括α1-、α2-、β- 和γ-球蛋白。
总蛋白的浓度对维持血液和组织之间水的正常平衡与交换是很重要的。
血清蛋白浓度较低，可能是由于吸收不良、合成受损引起的，或是由于出血或过度分解代谢导致蛋白损失而引起的，如肾病和肝病中观察到的情况，这种情况可能导致低蛋白血症。
在高免疫球蛋白血症（如多发性骨髓瘤和感染）或脱水情况下，可能发生高蛋白血症。
方法的原理本分析法采用双缩脲反应测定血清蛋白，其中碱性溶液中的二价铜离子与化合物（含 2 个或多个、与碳原子结合的酰胺基或肽基）反应，形成一种有色络合物4。
碱性 pH血清蛋白质类 + Cu++———— 紫色络合物紫色络合物以分光光度法在 550nm 处测定，以 700nm 作为空白波长。
在较宽的线性范围内，该络合物的密度与蛋白质浓度成正比5。
试剂五水合硫酸铜0.3g/dL氢氧化钠0.8g/dL碘化钾、酒石酸钾钠和叠氮化钠作为防腐剂。
注意事项1.当处理任何实验室试剂时，应遵守良好实验室安全规范(CLSI, GP17-A2)。
2.氢氧化钠具有腐蚀性，能引起烧伤。
不要用嘴吸取试剂。
如果吞服，应立即就医处理。
避免眼部和皮肤接触。
如发生眼部接触，立即用大量水清洗眼睛，并就医处理。
如果发生皮肤接触，用水清洗皮肤至少 15 分钟。
3.本试剂含叠氮化钠 <0.1%；叠氮化钠可与铅和铜水管反应，形成高爆炸性金属叠氮化物。
请参考化学品安全说明书中的危险、危害和安全信息。
4.就任何诊断试验方法而言，其结果应根据所有其它试验结果和患者的临床状况加以解释。
安捷伦产品目录
15
Real-Time PCR
16
Mx3000P QPCR System
17
Brilliant III Ultra-Fast SYBR Green QPCR and QRT-PCR Reagents
18
Brilliant III Ultra-Fast QPCR and QRT-PCR Reagents
Agilent / STRATAGENE
Agilent website: /genomics
Welgene | Agilent Stratagene
威健股份有限公司 | Stratagene 總代理
Table of Content
Table of Contents
/ XL1-Red Competent Cells SoloPack Gold Supercompetent Cells
/ TK Competent Cells Specialty Cells
/ Classic Cells / Fine Chemicals For Competent Cells
適用於 UNG 去汙染或 bisulphite
sequencing
適用於 TA Cloning
最高敏感性
取代傳統 Taq 的好選擇
-
2
威健股份有限公司 | Stratagene 總代理
PCR Enzyme & Instrument
Agilent SureCycler 8800
市場上領先的 cycling 速度和 sample 體積 10 ～ 100 μL 簡易快速可以選擇 96 well 和 384 well 操作盤 優秀的溫控設備讓各個 well 都能保持溫度的穩定 七吋的高解析度觸控螢幕讓操作上更為簡便 可以透過網路遠端操控儀器及監控儀器 Agilent 專業的技術支援可以幫助您應對各種 PCR 的問題
植物病害诊断试剂盒
植物病害诊断试剂盒美国阿格迪agdia 公司是全球最大的植物病害诊断试剂生产商，产品品种最多，可检测项目多达200多个。
包装规格最全,不同的包装规格适合不同规模的实验室。
从中您一定能发现适合您使用的产品。
选购试剂说明，请仔细阅读。
1，kit, 订货号PSAxxxxx/xxxx 或PSPxxxxx/xxxx 为完整的试剂盒包装，包括样品提取缓冲液、包被好抗体的微孔板（可拆分）、酶标记物、稀释液、缓冲液、底物发色剂、阳性质控（如果应该供应）。
特别注明Indirect ELISA 方法的kit 包括未包被的微孔板及联接用的抗体，所含有的其他组分同上。
2， Reagent Set, 订货号SRAxxxxx/xxxx ,XRAxxxxx/xxxx或SRPxxxxx/xxxx 只含有未包被的微孔板、包被需要的抗体或联接用的抗体、酶标记物。
其他试剂如样品提取缓冲液、稀释液、缓冲液、底物发色剂、质控物需另外订购或自己配制。
我公司销售原厂的上述试剂，详见目录。
3， Bacterial Reagent Set, 订货号BRAxxxxx/xxxx 只含有未包被的微孔板、包被需要的抗体或联接用的抗体、酶标记物。
其他试剂如样品提取缓冲液、稀释液、缓冲液、底物发色剂、质控物需另外订购或自己配制。
我公司销售原厂的上述试剂，详见目录。
4， Bacterial ID订货号BIDxxxxx/xxxx 为完整的试剂盒包装，包括样品提取缓冲液、包被好抗体的微孔板（可拆分）、酶标记物、稀释液、缓冲液、底物发色剂、质控（如果应该供应）。
用于鉴定培养基中或有病症植物提取液中的细菌。
操作简便快速。
5， PS A或SR A中的A代表碱性磷酸酶标记；PS P或SR P中的P代表过氧化物酶标记。
6， Immunostrip test, 为检试纸条，操作简单，几分钟内得到结果，非常适合于现场检测。
该试条必须与相应的样品提取缓冲液配套使用。
实验室需要单独购买该样品提取缓冲液，详见目录。
口腔科英语专业词汇
口腔科英语专业词汇翻译牵引钩hook铅毒性口炎lead stomatitis前导anterior guidance前弓anterior arch前弓区anterior arch area前磨牙premolars, bicuspid teeth ; 又称“双尖牙”。
X线头影测量机cephalometric X-ray machineX线头影测量片cephalometric roentgenogram[成釉器]星网状层stellate reticulum, enamel pulp; 又称“釉髓”。
[成釉器]中间层stratum intermedium[家族性]巨颌症cherubism[牙]根管root canal[牙]根尖孔apical foramen[牙]龈瘤epulis咬合occlusion; 下颌静止位时，上下牙的接触关系。
咬合叉bite fork, face-bow fork咬合叉固定夹bite fork clamp咬合垂直距离occlusal vertical dimension咬合堤occlusal rim咬合垫occlusal pad咬合干扰occlusal interference咬合夹板occlusal splint咬合架articulator咬合间记录interocclusal record咬合力occlusal force, biting force咬合力计occlusometer咬合面occlusal surface咬合面窝occlusal fossa咬合磨损occlusal wear咬合平衡occlusal equilibration咬合平面occlusal plane咬合平面导板occlusal guide plate咬合平面规occlusal plane guide咬合托bite plate咬合紊乱occlusion disorder咬合型occlusal pattern咬合学occlusion咬合翼片bite wing film咬合缘occlusal margin咬合支托occlusal rest咬合重建occlusal reconstruction咬合片occlusal filmⅠ类错咬合class ⅠmalocclusionⅠ型卡环type Ⅰclasp, pull type clasp, Aker clasp; 又称“拉型卡环”、“阿克卡环”。
超高效液相色谱-串联质谱法测定化妆品中15种N-亚硝胺化合物
第42 卷第 11 期2023 年11 月Vol.42 No.111469~1478分析测试学报FENXI CESHI XUEBAO（Journal of Instrumental Analysis）超高效液相色谱-串联质谱法测定化妆品中15种N-亚硝胺化合物汪毅1，梁文耀1，何国山1，陈张好2，周智明2，吴谦1，席绍峰1，谭建华1*（1．广州质量监督检测研究院，国家化妆品质量检验检测中心（广州），广东广州511447；2．广东省药品检验所，广东广州510663）摘要：采用超高效液相色谱-串联质谱（UPLC-MS/MS）建立了化妆品中15种痕量N-亚硝胺化合物的分析方法。
水剂样品以水或乙腈分组超声提取，膏霜乳液样品采用亚铁氰化钾-乙酸锌溶液沉淀大分子或者饱和氯化钠-乙腈盐析分组处理后，以Agilent Poroshell 120 SB-Aq（100 mm×3.0 mm，2.7 μm）色谱柱分离，经大气压化学电离源（APCI）电离，多反应监测模式检测，以同位素内标法定量。
结果表明，15种N-亚硝胺化合物在相应质量浓度范围内线性关系良好（r2＞0.995），检出限和定量下限分别为5~15 ng/g和15~45 ng/g。
水、乳、膏霜3种化妆品基质在25、50、100 ng/g加标水平下的平均回收率为88.0%~111%，相对标准偏差（RSD，n=6）为1.4%~9.8%。
该方法用于市售化妆品检测，发现13批次样品检出N-亚硝基二乙醇胺（NDELA），其中1批次超限量值。
方法的专属性强，灵敏度高，精密度好，解决了N-亚硝胺化合物稳定性差、易被干扰等问题，适用于化妆品中15种N-亚硝胺化合物的痕量测定。
关键词：N-亚硝胺化合物；化妆品；超高效液相色谱-串联质谱法（UPLC-MS/MS）；大气压化学电离源中图分类号：O657.63；O623.732文献标识码：A 文章编号：1004-4957（2023）11-1469-10 Determination of Fifteen N-nitrosamine Compounds in Cosmetics by Ultra Performance Liquid Chromatography-TandemMass SpectrometryWANG Yi1，LIANG Wen-yao1，HE Guo-shan1，CHEN Zhang-hao2，ZHOU Zhi-ming2，WU Qian1，XI Shao-feng1，TAN Jian-hua1*（1．Guangzhou Quality Supervision and Testing Institute，National Quality Supervision and Testing Center for Cosmetics（Guangzhou），Guangzhou 511447，China；2．Guangdong Institute for Drug Control，Guangzhou 510663）Abstract：An ultra performance liquid chromatography-tandem mass spectrometric（UPLC-MS/MS）method was established for detecting 15 trace N-nitrosamine compounds in cosmetics. The final estab⁃lished method involved ultrasonic extraction of cosmetics using water or acetonitrile for different com⁃pounds. The samples were treated with potassium ferrocyanide-zinc acetate solution for precipitating macromolecules or saturated sodium chloride-acetonitrile for salting out.An Agilent Poroshell 120 SB-Aq（100 mm × 3.0 mm，2.7 μm） chromatography column was used for separation，followed by atmospheric pressure chemical ionization（APCI） source and multiple reaction monitoring mode detec⁃tion in the isotope internal standard method for quantification. The result showed good linearity（r2> 0.995） for the 15 N-nitrosamine compounds in their respective concentration ranges，with detection and quantitation limits of 5-15 ng/g and 15-45 ng/g，respectively.The average recoveries for the three cosmetic matrices（aqueous，emulsion，cream） at spiked levels of 25，50，100 ng/g were be⁃tween 88.0% and 111%，with relative standard deviations（RSD，n=6） of 1.4%-9.8%. The method was applied to the detection of commercial cosmetics and N-nitrosodiethanolamine（NDELA） was de⁃tected in 13 batches，with one batch exceeding the limit. The strong specificity，high sensitivity，and good precision made the method could solve the problems of poor stability and easy interference ofdoi：10.19969/j.fxcsxb.23051602收稿日期：2023－05－16；修回日期：2023－06－10基金项目：广东省药品监督管理局化妆品风险评估重点实验室专项（2021ZDZ03）；广东省市场监督管理局科技项目（2022CZ06）∗通讯作者：谭建华，博士，正高级工程师，研究方向：色谱－质谱检测技术研究，E-mail：tanjianhua0734@第 42 卷分析测试学报N-nitrosamine compounds，and was suitable for the trace determination of 15 N-nitrosamine com⁃pounds in cosmetics.Key words：N-nitrosamine compounds；cosmetics；ultra performance liquid chromatography-tan⁃dem mass spectrometry（UPLC-MS/MS）；atmospheric pressure chemical ionization（APCI） sourceN-亚硝胺化合物是一类具有N-亚硝基结构的化合物，因取代基的不同，形成了种类繁多的同系物，目前已发现超过300种［1］。
IPI549-SDS-MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Oct.-12-2018Print Date:Oct.-12-20181. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :IPI549Catalog No. :HY-100716CAS No. :1693758-51-81.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureGHS Classification in accordance with 29 CFR 1910 (OSHA HCS)Acute toxicity, Oral (Category 4), H302Acute aquatic toxicity (Category 1), H400Chronic aquatic toxicity (Category 1), H4132.2 GHS Label elements, including precautionary statementsPictogramSignal word No data availableHazard statement(s)H302 Harmful if swallowed.H413 Very toxic to aquatic life with long lasting effects.Precautionary statement(s)P264 Wash skin thoroughly after handling.P270 Do not eat, drink or smoke when using this product.P273 Avoid release to the environment.P301 + P312 IF SWALLOWED: Call a POISON CENTER or doctor ⁄physician if you feel unwell.P333 Rinse mouth.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:IPI-549;IPI 549Formula:C30H24N8O2Molecular Weight:528.56CAS No. :1693758-51-84. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to yellow (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGUN number: 3077Class: 12Packing group: IIIEMS-No: F-A, S-FProper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.Marine pollutant: Marine pollutantIATAUN number: 3077Class: 12Packing group: IIIProper shipping name: Environmentally hazardous substance, solid, n.o.s.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 316 Components:This material does not contain any chemical components with known CAS numbers that exceed thethres33&33U_HKSCS33&MingLiU_HKSCS3333333333316. OTHER INFORMATIONCopyright 2018 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
Keap1
非小细胞肺癌(non-small cell lung cancer，NSCLC)发病率占据肺癌的75%~80%。
肿瘤细胞进展快且易扩散转移，临床常采用手术、放化疗等进行治疗，但5年生存率低于60%[1-2]。
氧化应激是由活性氧(ROS)生成量增加所致，ROS积累可诱导肺癌细胞凋亡，清除ROS 可阻止癌细胞凋亡，即肺癌细胞存活依赖于癌细胞自身抗氧化能力[3]。
Kelch样环氧氯丙烷相关蛋白-1 (kelch-like epichlorohydrin-associated protein-1，Keap1)/核因子E2相关因子2(nuclear factor E2related factor 2，Nrf2)信号通路在癌症中发挥重要调控作用，氧化应激可激活Keap1，促使Keap1-Nrf2复合物裂解，Nrf2转移至细胞核内，可激活下游靶基因表达，参与肺癌发生发展过程[4]。
Nrf2可维持氧化还原稳态，ROS侵袭细胞时，Nrf2可进入细胞核，结合抗氧化反应元件(ARE)转录编码各种抗氧化蛋白、代谢酶基因，抑制氧化应激反应[5-6]。
目前氧化应激、Keap1/Nrf2信号通路在NSCLC发生过程中的机制尚未明确。
基于此，本研究尝试分析Keap1/Nrf2信号通路与临床病理参数、氧化应激指标的相关性，探讨其在NSCLC氧化应激机制中的作用，为临床研制新药提供参考依据。
1资料与方法1.1一般资料选取2017年4月至2020年4月郑州市第三人民医院收治的100例NSCLC患者为研究对象。
纳入标准：符合NSCLC诊断标准[7]；术前未接受放化疗、免疫治疗者；预计生存期≥6个月；符合手术适应证、禁忌证；Karnofsky功能状态评分≥70分；签署知情同意书。
排除标准：合并凝血功能障碍、肝肾功能障碍、其他恶性肿瘤者；伴有急/慢性感染者；伴有精神疾病者；既往腹部相关外科手术史者。
所有患者均行肺癌根治性切除术，术中收集癌组织、癌旁组织(距离癌组织5cm范围内正常组织)，其中男性63例，女性37例；年龄46~67岁，平均(56.32±3.16)岁；体质量指数(BMI)17~30kg/m2，平均(23.16±2.03)kg/m2；病理类型：鳞癌58例、腺癌42例；病理分级[8]：Ⅰ~Ⅱ级51例、Ⅲ级49例；T分期[9]：T1~T253例、T3~T447例；N分期：N055例、N1~N245例。
3-氧代环丁烷-1,1-二羧酸,二异丙酯 hplc
3-氧代环丁烷-1,1-二羧酸,二异丙酯hplc3-氧代环丁烷-1,1-二羧酸,二异丙酯（3-Oxocyclobutanecarboxylic Acid Diisopropyl Ester）是一种有机化合物。
HPLC（高效液相色谱，High-Performance Liquid Chromatography）是一种分离和分析化学物质的技术。
结合起来，3-氧代环丁烷-1,1-二羧酸，二异丙酯HPLC 可以指涉使用HPLC技术对3-氧代环丁烷-1,1-二羧酸，二异丙酯进行分析和检测。
HPLC是一种广泛应用的分离技术，它基于化学物质在液相中的相互作用和分配行为进行分离。
该技术涉及一组主要组件：流动相（溶剂）、色谱柱、样品进样系统、检测器和数据处理设备。
流动相：流动相是溶解化合物样品并在色谱柱中传输化合物的溶剂系统。
它通常是由溶剂混合物组成的，可根据目标分析的性质和要求选择不同的溶剂系统。
色谱柱：色谱柱是分离化合物的关键部件，根据分析目标的不同选择合适的柱子。
在HPLC中常用的柱子类型包括反相柱、离子交换柱、大小分子筛柱等。
反相柱是最常用的类型，其中常用的填充剂包括碳链和亲水基团。
样品进样系统：样品进样系统将要分析的化合物溶液引入色谱柱。
它可以是自动进样器或手动进样器，确保准确而重复的样品进样。
检测器：检测器用于检测样品在流动相中的组分。
常见的HPLC检测器包括紫外-可见检测器（UV-Vis）、荧光检测器、折光率检测器等。
选用适当的检测器可以根据化合物的属性和要求获得准确的定量和定性数据。
数据处理设备：HPLC仪器通常与计算机或数据处理设备连接，用于记录和分析检测器产生的信号。
数据处理设备可以对色谱图进行处理、数据整合和分析，并生成定量和定性的结果。
通过调节流动相的组成、柱温、流速和检测器参数等条件，对3-氧代环丁烷-1,1-二羧酸，二异丙酯的HPLC分析可以实现其分离和定量检测，同时可以通过与参考标准品比对来确定目标化合物的浓度。
英语国际会议PPT课件
Materials and Methods
Patients
Materials and Methods
Cytokine assessment by ELISA
Western blot
Cell isolation and culture
Statistical analysis
7
Methods
IFN-c-induced protein of 10-kDa (IP-10)/CXCL10
we studied the effects of α-toxin on Th1- and Th2related chemokines in macrophages from patients with AD and psoriasis where the intrinsic abnormal and different chemokines production profile is well defined.
13
Figure 3 Punch biopsies (3 mm) from healthy individuals were left either unstimulated (A) or stimulated with a-toxin (100 ng/ ml) (B) or IFN-c (100 ng/ml) (C) for 24 h at 37C. 5-lm paraffin sections were stained for CXCL10 along with appropriate isotype as well as CD68.
16
Low effect of a-toxin on CXCL10 induction (Th1-related chemokine) in macrophages from patients with AD
抗单纯疱疹病毒1_型的IgY_制备及其生物学活性检测
第 50 卷第 2 期2024年 3 月吉林大学学报（医学版）Journal of Jilin University（Medicine Edition）Vol.50 No.2Mar.2024DOI：10.13481/j.1671‐587X.20240202抗单纯疱疹病毒1型的IgY制备及其生物学活性检测苏海涛1, 翟玥2, 宋秀玲2, 徐坤2,3（1. 吉林省疾病预防控制中心寄生虫病预防控制所，吉林长春130062；2. 吉林大学公共卫生学院卫生检验教研室，吉林长春130021；3. 湖南师范大学医学院食品与营养卫生教研室，湖南长沙410013）［摘要］目的目的：制备抗单纯疱疹病毒1型（HSV-1）的卵黄抗体（IgY），探讨该抗体的生物学活性，阐明其抗HSV-1的能力。
方法方法：制备HSV-1灭活疫苗，采用鸡胸多点注射法免疫高产蛋鸡，采用聚乙二醇-6000（PEG-6000）法提纯IgY，采用间接ELISA法、十二烷基硫酸钠-聚丙烯酰胺凝胶电泳（SDS-PAGE）技术和蛋白浓度定量试剂盒测定IgY效价、纯度及蛋白水平，采用间接ELISA法检测IgY中和病毒的能力，测定病毒阻断率，以Vero细胞为病毒感染靶细胞，测定不同抗体浓度（0.015 60、0.031 25、0.062 50、0.125 00、0.500 00、和1.000 00 g·L－1）作用后细胞病变效应（CPE），根据CPE程度测定IgY体外抗HSV-1能力。
结果结果：制备的IgY效价随免疫时间逐渐升高，达到1/1 024 000后保持稳定；IgY轻链重链条带清晰；IgY平均蛋白水平为11.544 g·L－1；IgY对HSV-1的阻断率可高达77.90%；HSV-1致CPE程度随抗体浓度升高而逐渐降低，当IgY浓度达到0.500 00 g·L－1及以上时，25%以下细胞（甚至无细胞）发生病变。
结论结论：成功制备出抗HSV-1的IgY，该抗体对HSV-1具有明显的中和阻断能力和体外抑制活性，可用于药物及诊断方法的开发。
3%高渗盐水联合吸入用复方异丙托溴铵溶液雾化吸入治疗呼吸道合胞病毒肺炎的效果
CHINA MODERN MEDICINE Vol.28No.12April 20213%高渗盐水联合吸入用复方异丙托溴铵溶液雾化吸入治疗呼吸道合胞病毒肺炎的效果张招文胡冰王贵莲曾凯丹胡华著江西省宜春市人民医院儿科,江西宜春336000[摘要]目的探讨3%高渗盐水联合吸入用复方异丙托溴铵溶液雾化吸入治疗呼吸道合胞病毒肺炎的效果。
方法选取2015年1月~2016年12月江西省宜春市人民医院收治的195例呼吸道合胞病毒肺炎患儿作为研究对象,按照随机数字表法分为治疗一组(65例)、治疗二组(65例)、治疗三组(65例)。
治疗一组采用3%高渗盐水4mL+吸入用复方异丙托溴铵溶液雾化吸入;治疗二组采用生理盐水4mL+吸入用复方异丙托溴铵溶液雾化吸入;治疗三组采用0.9%氯化钠溶液2mL+硫酸特布他林雾化液+布地奈德混悬液雾化吸入。
比较三组患儿的咳嗽消失时间、气促消失时间、喘憋消失时间、肺部体征消失时间、住院时间及治疗效果。
结果治疗一组咳嗽消失时间、气促消失时间、喘憋消失时间、肺部体征消失时间及住院时间均短于治疗二组、治疗三组,差异有统计学意义(P <0.05);但治疗二组与治疗三组的咳嗽消失时间、气促消失时间、喘憋消失时间、肺部体征消失时间及住院时间比较,差异均无统计学意义(P >0.05)。
治疗一组患儿的治疗总有效率高于治疗二组、治疗三组,差异有统计学意(P <0.05);但治疗二组、治疗三组的治疗总有效率比较,差异无统计学意义(P >0.05)。
结论3%高渗盐水联合吸入用复方异丙托溴铵溶液雾化吸入治疗呼吸道合胞病毒肺炎的治愈率高,能够尽快解除患儿的咳嗽、气促、喘憋、肺部体征,缩短住院时间,效果明显,值得推广。
[关键词]3%高渗盐水;呼吸道合胞病毒;肺炎;吸入用复方异丙托溴铵溶液[中图分类号]R562.2[文献标识码]A [文章编号]1674-4721(2021)4(c)-0115-04Effect of 3%hypertonic saline combined with Compound Ipratropium Bromide Solution atomization inhalation in the treatment of respiratory syncytial virus pneumoniaZHANG Zhao-wen HU Bing WANG Gui-lian ZENG Kai-Dan HU Hua-zhuDepartment of Pediatrics,People′s Hospital of Yichun City,Jiangxi Province,Yichun 336000,China[Abstract]Objective To investigate the effect of 3%hypertonic saline combined with Compound Ipratropium Bromide Solution atomization inhalation in the treatment of respiratory syncytial virus pneumonia.Methods A total of 195chil⁃dren with respiratory syncytial virus pneumonia who were treated in People′s Hospital of Yichun City,Jiangxi Province from January 2015to December 2016were selected as the research subjects.According to the random number table method,they were divided into treatment group 1(65cases),treatment group 2(65cases)and treatment group 3(65cas⁃es).The treatment group 1received 3%hypertonic saline 4mL +Compound Ipratropium Bromide Solution atomized inhalation.The treatment group 2was treated with 4mL of normal saline +Compound Ipratropium Bromide Solution at⁃omized inhalation.The treatment group 3was treated with 0.9%sodium chloride solution 2mL +Terbutaline Sulfate Atomized Solution +Budesonide Suspension atomized inhalation.The time of cough disappearance,shortness of breath disappearance,asthma disappearance,lung signs disappearance,hospital stay and treatment effect of the three groups were compared.Results The disappearance time of cough,shortness of breath,dyspnea,lung signs and hospitalization time in treatment group 1were shorter than those in treatment group 2and treatment group 3,with statistical signifi⁃cances (P <0.05).However,there were no significant differences in the disappearance time of cough,shortness of breath,dyspnea,lung signs and hospitalization time between the treatment group 2and treatment group 3(P >0.05).The total effective rate of treatment group 1was higher than that of treatment group 2and treatment group 3,and the difference was statistically significant (P <0.05).However,there was no significant difference in the total effective rate between the treatment group 2and treatment group 3(P >0.05).Conclusion 3%hypertonic saline combined with Compound Iprat⁃ropium Bromide Solution atomization inhalation in the treatment of respiratory syncytial virus pneumonia has a high cure rate,which can relieve cough,shortness of breath,shortness of breath,lung signs and shorten the duration of hos⁃pitalization as soon as possible.It′s worth popularizing.[Key words]3%hypertonic saline;Respiratory syncy⁃tial virus;Pneumonia;Inhalation with Compound Iprat⁃ropium Bromide Solution[基金项目]江西省宜春市社会发展类科技计划项目(JXYC 2016KSC003)115呼吸道合胞病毒肺炎是最常见的病毒性肺炎,多见于婴幼儿,尤其1岁以内婴儿,临床主要表现为咳嗽、呼吸困难、气促、喘憋、面色发绀等,呼吸道分泌物多,易出现气道堵塞,导致心、肺、脑、肾等多脏器功能衰竭,直接威胁广大患儿的生命健康[1]。